Cargando…

What are we trying to prevent in Alzheimer disease?

Within aging societies, the number of individuals suffering from Alzheimer disease (AD) is constistently increasing. This is paralleled by intense research aimed at improving treatment options and potentially even fostering effective prevention. The discussion on relevant outcomes of such interventi...

Descripción completa

Detalles Bibliográficos
Autor principal:	Jessen, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Les Laboratoires Servier 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780361/ https://www.ncbi.nlm.nih.gov/pubmed/31607778

Ejemplares similares

Depression—an underrecognized target for prevention of dementia in Alzheimer’s disease
por: Dafsari, Forugh S., et al.
Publicado: (2020)

Social cognitive impairment and autism: what are we trying to explain?
por: Leekam, Susan
Publicado: (2016)

When We Study the Ability to Attend, What Exactly Are We Trying to Understand?
por: Tsotsos, John K.
Publicado: (2022)

The gut microbiome in Alzheimer’s disease: what we know and what remains to be explored
por: Chandra, Sidhanth, et al.
Publicado: (2023)

Careers. At least we should try.
por: Signy, A. G.
Publicado: (1971)

Cannabis use in first episode psychosis: what we have tried and why it hasn’t worked
por: McDonell, Michael G., et al.
Publicado: (2019)

What We Know and What We Don't Know About Preventing Stroke
por: Burch, Druin
Publicado: (2014)

Biomarkers to Measure Treatment Effects in Alzheimer's Disease: What Should We Look for?
por: Rockwood, Kenneth
Publicado: (2011)

CSF beta-amyloid 1–42 – what are we measuring in Alzheimer's disease?
por: Hu, William T, et al.
Publicado: (2015)

Are we Aware of what we are, we are what we Eat- An Epidemiological Survey
por: Kaur, Manpreet, et al.
Publicado: (2008)

Vitamin E and Alzheimer’s disease: what do we know so far?
por: Browne, Declan, et al.
Publicado: (2019)

What do we know from clinical trials on exercise and Alzheimer's disease?
por: Shen, Yong, et al.
Publicado: (2016)

Alzheimer’s Disease: What Can We Learn From the Peripheral Olfactory System?
por: Dibattista, Michele, et al.
Publicado: (2020)

Neuropsychiatric Disturbances in Alzheimer’s Disease: What Have We Learned from Neuropathological Studies?
por: Van Dam, Debby, et al.
Publicado: (2016)

Commentary: Missing the mark but we must keep trying
por: Vo, Thin X., et al.
Publicado: (2020)

COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know
por: Dhawan, Rahul, et al.
Publicado: (2020)

The aging penis: what is it trying to tell us?
por: Rajfer, Jacob
Publicado: (2012)

Links between COVID-19 and Alzheimer’s Disease—What Do We Already Know?
por: Rudnicka-Drożak, Ewa, et al.
Publicado: (2023)

Neurodegeneration of the retina in mouse models of Alzheimer’s disease: what can we learn from the retina?
por: Chiu, Kin, et al.
Publicado: (2011)

Portion Size: What We Know and What We Need to Know
por: Benton, David
Publicado: (2015)

Opioid overdose prevention and naloxone rescue kits: what we know and what we don’t know
por: Kerensky, Todd, et al.
Publicado: (2017)

Protein energy wasting; what is it and what can we do to prevent it?
por: Rees, Lesley
Publicado: (2019)

Transgender People and HIV Prevention: What We Know and What We Need to Know, a Call to Action
por: Mayer, Kenneth H., et al.
Publicado: (2016)

International Trade and Investment and Food Systems: What We Know, What We Don’t Know, and What We Don’t Know We Don’t Know
por: Schram, Ashley, et al.
Publicado: (2020)

Peri-implant disease: what we know and what we need to know
por: Valente, Nicola Alberto, et al.
Publicado: (2016)

What We Seem and What We Are
por: Towner, Ausburn
Publicado: (1880)

What can we learn from study of Alzheimer's disease in patients with Down syndrome for early-onset Alzheimer's disease in the general population?
por: Wallace, Robyn A, et al.
Publicado: (2011)

Tri11, tri3, and tri4 genes are required for trichodermin biosynthesis of Trichoderma brevicompactum
por: Shentu, Xuping, et al.
Publicado: (2018)

Coexisting Coronary and Carotid Artery Disease: What We Did, What Happened
por: Güney, Mehmet Raşit, et al.
Publicado: (2022)

Metal wear particles: What we know, what we do not know, and why
por: Billi, Fabrizio, et al.
Publicado: (2009)

What happens when we modify mosquitoes for disease prevention? A systematic review
por: Nazareth, Teresa, et al.
Publicado: (2020)

What we see is what we touch? Sex estimation on the pelvis in virtual anthropology
por: Braun, Sandra, et al.
Publicado: (2023)

Animal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under Development
por: Delire, Bénédicte, et al.
Publicado: (2015)

A 3D Human Tri-Culture System Modeling Neurodegeneration and Neuroinflammation in Alzheimer’s Disease
por: Park, Joseph, et al.
Publicado: (2018)

Optimum sedation and analgesia in critical illness: we need to keep trying
por: Lavery, Gavin G
Publicado: (2004)

The Geography of the Alzheimer’s Disease Mortality in Spain: Should We Focus on Industrial Pollutants Prevention?
por: Martínez-Solanas, Èrica, et al.
Publicado: (2017)

Geriatric Radiation Oncology: What We Know and What Can We Do Better?
por: Roeder, Falk, et al.
Publicado: (2023)

Cardiac surgery and the coronavirus disease 2019 pandemic: What we know, what we do not know, and what we need to do
por: Bakaeen, Faisal G., et al.
Publicado: (2020)

Biomarkers in Alzheimer disease: are we there yet?
por: Generoso, Jaqueline S., et al.
Publicado: (2020)

What We Know of Elephantiasis
por: Christophers, S. R.
Publicado: (1907)

Cannot write session to /tmp/vufind_sessions/sess_558e3t88jbdtmuj1vh1835h80k